Clinical trials: Non-Tuberculous Mycobacterial (NTM) Infections
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease.
- Trial name
- NCT05327803
- Testing
- Epetraborole
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 177 people
- Sponsor
- AN2 Therapeutics, Inc
Bronchiectasis, Non-tuberculous Mycobacterial
Prevalence and Characteristics of Patients With Bronchiectasis Comorbid Nontuberculous Mycobacteria
The purpose of this study is to Understand the prevalence of non-tuberculous mycobacterial(NTM) infections in the middle-aged and old women patients with bronchiectasis in Mainland China, and explore the characteristics of…
- Trial name
- NCT03594032
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Bin Cao
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Pulmonary Disease, Pulmonary Infection
A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea.
- Conditions
- Pulmonary Disease, Pulmonary Infection, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NTM-KOREA (NCT03934034)
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Hospital
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
MAC Lung Disease, Treatment Refractory MAC Lung Disease
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
- Conditions
- MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
- Trial name
- ICoN-1 (NCT06418711)
- Testing
- Clofazimine Inhalation Suspension
- Where
- 99 sites in United States, Australia and 3 more
- Volunteers
- 132 people
- Sponsor
- Mannkind Corporation
Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with…
- Trial name
- NCT07228702
- Testing
- Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health
Mycobacterium Infections, Nontuberculous
A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections
The study aims to address the following aims 1. To provide an overview of the epidemiology of the patients who are managed in the Singapore General Hospital for NTM infections. 2.
- Trial name
- NCT02355015
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Nontuberculous Mycobacterium Infection
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask.
- Trial name
- NCT03748992
- Testing
- gNO
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Non-Tuberculous Mycobacterial (NTM) Infections
Treatment Monitoring for NTM Infections With a Symptom Diary
The primary aim of the study is to investigate the correlation between patient-reported symptoms recorded in the diary and the microbiological and radiological disease course in patients with pulmonary infections caused by…
- Trial name
- NTMdiary (NCT07131774)
- Testing
- Filling in a symptom diary
- Where
- 3 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Research Center Borstel
Mycobacterium Infections, Nontuberculous
Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
The trial is an open-label, non-controlled, multicenter, pilot clinical trial of inhaled molgramostim (recombinant human granulocyte-macrophage colony stimulating factor; rhGM-CSF) in subjects with persistent pulmonary…
- Trial name
- OPTIMA (NCT03421743)
- Testing
- Inhaled molgramostim, Antimycobacterial regimen
- Where
- 5 sites in Australia, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Savara Inc.
Non-Tuberculous Mycobacterial Pneumonia
Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection
An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment…
- Trial name
- NCT03473314
- Testing
- Nitric Oxide gas at 160ppm
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of British Columbia
Non-Tuberculous Mycobacterial Pneumonia, Tuberculosis
Mycobacteria Registry Study: Prospective Observational Study in Austria
The goal of this non-interventional registry study is to systematically collect epidemiological and clinical data throughout the treatment course to learn about effectiveness of treatments.
- Trial name
- NCT06522347
- Where
- 3 sites in Austria
- Volunteers
- 1,000 people
- Sponsor
- Ludwig Boltzmann Institute for Lung Health
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Tuberculosis, Pulmonary, Non-Tuberculous Mycobacterial Pneumonia
Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis
Microbiome in lower respiratory diseases is not sufficiently known yet. The objective of this study is to investigate microbiome in patients who present with hemoptysis, and those with pulmonary tuberculosis, non-tuberculous…
- Conditions
- Tuberculosis, Pulmonary, Non-Tuberculous Mycobacterial Pneumonia, Lung Cancer, Hemoptysis
- Trial name
- NCT04079400
- Volunteers
- 43 people
- Sponsor
- Gachon University Gil Medical Center
Sporotrichosis, Chromomycosis
A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
In Costa Rica there are some descriptive studies of some of these rare infectious diseases (sporotrichosis, chromomycosis and mycetomas); however, there are no recent published reports.
- Conditions
- Sporotrichosis, Chromomycosis, Actinomycosis, Nocardiosis
- Trial name
- NCT06523998
- Where
- 3 sites in Costa Rica
- Volunteers
- 95 people
- Sponsor
- Caja Costarricense de Seguro Social
Non-Tuberculous Mycobacterial (NTM) Infections
Lamprene Multiple Patient Program
Lamprene®/Clofazimine, is a product of the pharmaceutical company named Novartis Pharmaceuticals Corporation. Lamprene®/Clofazimine is approved by FDA (the U.S Food and Drug Administration) for the treatment of leprosy.
- Trial name
- NCT04334070
- Testing
- Lamprene®/Clofazimine
- Sponsor
- Novartis Pharmaceuticals
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
The purpose of this open-label, multicenter, non-randomized, pilot study is to assess the safety of high dose intermittent iNO for treatment of NTM infection in CF and non-CF patients.
- Conditions
- Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis, Mycobacterial Pneumonia, Mycobacterium Abscessus Infection
- Trial name
- NCT04685720
- Testing
- LungFit
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Beyond Air Inc.